Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRI plus cetuximab vs bevacizumab in first-line mCRC with RAS/BRAF discordance between tissue and liquid biopsy
2024-517863-22-00Phase 3Authorised
- Sponsor
- Azienda USL-IRCCS di Reggio Emilia
- Start
- Nov 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of cetuximab, bevacizumab, irinotecan, fluorouracil and levoleucovorin in metastatic colon cancer (mCRC) (2 arms), sponsored by Azienda USL-IRCCS di Reggio Emilia. Primary endpoint: Progression-free survival. Planned start Nov 2024; status: authorised.
02
Drugs
cetuximabbevacizumabirinotecanfluorouracillevoleucovorin
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on 2024-517863-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517863-22-00.